JVTCX | VSGAX | JVTCX / VSGAX | |
Total Expense Ratio | 1.95 | 0.07 | 2,786% |
Annual Report Gross Expense Ratio | 2.10 | 0.07 | 3,000% |
Fund Existence | 14 years | 14 years | - |
Gain YTD | -1.431 | -1.038 | 138% |
Front Load | N/A | N/A | - |
Min. Initial Investment | 2500 | 3000 | 83% |
Min. Initial Investment IRA | N/A | N/A | - |
Net Assets | 2.97B | 35B | 8% |
Annual Yield % from dividends | 0.00 | 0.54 | - |
Returns for 1 year | -2.78 | 11.79 | -24% |
Returns for 3 years | 7.77 | 39.54 | 20% |
Returns for 5 years | -8.27 | 38.43 | -22% |
Returns for 10 years | -1.70 | 112.31 | -2% |
1 Day | |||
---|---|---|---|
STOCK / NAME | Price $ | Chg $ | Chg % |
CNTB | 1.06 | 0.08 | +8.16% |
Connect Biopharma Holdings Limited | |||
CDLR | 20.84 | 0.97 | +4.88% |
Cadeler A/S American Depositary Share (each representing four (4) | |||
SIGIP | 16.78 | 0.12 | +0.72% |
Selective Insurance Group | |||
DSGX | 102.04 | 0.39 | +0.38% |
Descartes Systems Group | |||
FULC | 6.84 | -0.04 | -0.58% |
Fulcrum Therapeutics |